Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ.

Research output: Contribution to journalArticlepeer-review


Women with a diagnosis of ductal carcinoma in situ (DCIS) have a high risk of developing a second breast event (SBE). The immune system might play a role in trying to prevent a SBE. Patients diagnosed with DCIS were identified in the population-based cancer registry of Area Vasta Romagna from 1997 to 2010. Median follow-up is 8.5 years. Tumor-infiltrating lymphocytes (TILs) were evaluated both in index DCIS and in SBE. The main endpoint was to assess the association between TILs' levels in index DCIS and risk of a SBE. Out of 496 DCIS patients, 100 SBEs (20.2 were identified: 55 ipsilateral (11.1 and 43 contralateral (8.7. The distribution of TILs was heterogeneous, but significantly associated with grade, necrosis, screen detection and type of surgery. Patients stratified according to TILs percentage (≤5textgreater5 did not show a statistically significant difference in the 5-year cumulative incidence of SBEs: 14.9951.3-19.1) and 11.095 6.9-16.2), respectively (p = 0.147). In the subgroup of patients who did not receive radiotherapy, TILs textgreater5HR 0.34, 95.14-0.82, p = 0.016). Although we did not find any significant association between TILs and SBE, further studies evaluating their role according to radiotherapy are warranted.
Original languageEnglish
Pages (from-to)1486
Number of pages1
JournalFrontiers in Oncology
Publication statusPublished - 2020


  • radiotherapy
  • tumor recurrence
  • breast conserving surgery
  • ductal carcinoma in situ
  • second breast event
  • tumor infiltrating lymphocytes


Dive into the research topics of 'Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ.'. Together they form a unique fingerprint.

Cite this